Recently, Jiang et al. reported that EGFR-activating mutations in NSCLC co-occurred with mutations in genes participating in most key signalling pathways and biological processes, including receptors of different classes, key regulators involved in genome and epigenome stability, the PI3K–AKT–mTOR pathway, and the TP53/apoptosis pathway [56]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.